E-PROT-26
Ontology highlight
ABSTRACT:
PROVIDER: E-PROT-26 | ExpressionAtlas | 2021-05-25
REPOSITORIES: ExpressionAtlas
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| E-PROT-26-analysis-methods.tsv | Tabular | |||
| E-PROT-26-configuration.xml | Xml | |||
| E-PROT-26-factors.xml | Xml | |||
| E-PROT-26.condensed-sdrf.tsv | Tabular | |||
| E-PROT-26.idf.txt | Idf |
Items per page: 5 1 - 5 of 12 |
Similar Datasets
Project description:Systems-wide quantitative proteomic study of breast cancer tumours
2021-05-25 | E-PROT-27 | ExpressionAtlas
Project description:Integrative proteomic profiling of ovarian cancer cell lines
2021-05-25 | E-PROT-28 | ExpressionAtlas
Project description:Proteome profiling of breast cancer biopsies reveals a wound healing signature of cancer-associated fibroblasts - tumor-distant tissue sections
2022-01-06 | E-PROT-37 | ExpressionAtlas
Project description:Transcription profiling by array of human breast cancer mammospheres and breast tumors
2025-01-24 | E-GEOD-7515 | ExpressionAtlas
Project description:Systems-wide profiling of breast cancer has so far built on RNA and DNA analysis by microarray and sequencing techniques. Dramatic developments in proteomic technologies now enable very deep profiling of clinical samples, with high identification and quantification accuracy. We analyzed 40 estrogen receptor positive (luminal), Her2 positive and triple negative breast tumors and reached a quantitative depth of more than 10,000 proteins. Comparison to mRNA classifiers revealed multiple discrepancies between proteins and mRNA markers of breast cancer subtypes. These proteomic profiles identified functional differences between breast cancer subtypes, related to energy metabolism, cell growth, mRNA translation and cell-cell communication. Furthermore, we derived a 19-protein predictive signature, which discriminates between the breast cancer subtypes, through Support Vector Machine (SVM)-based classification and feature selection. The deep proteome profiles also revealed novel features of breast cancer subtypes, which may be the basis for future development of subtype specific therapeutics.
2016-01-05 | PXD002619 | Pride
Project description:Gene expression profiling of LCM captured breast cancer cells
2025-01-24 | E-GEOD-54002 | ExpressionAtlas
Project description:Transcription profiling of human pre-malignant breast cancer samples
2025-01-24 | E-GEOD-7377 | ExpressionAtlas
Project description:Early Dysregulation of Cell Adhesion and Extracellular Matrix Pathways in Breast Cancer Progression
2025-01-24 | E-GEOD-16873 | ExpressionAtlas
Project description:Systems-wide profiling of breast cancer has so far built on RNA and DNA analysis by microarray and sequencing techniques. Dramatic developments in proteomic technologies now enable very deep profiling of clinical samples, with high identification and quantification accuracy. We analyzed 40 estrogen receptor positive (luminal), Her2 positive and triple negative breast tumors and reached a quantitative depth of more than 10,000 proteins. Comparison to mRNA classifiers revealed multiple discrepancies between proteins and mRNA markers of breast cancer subtypes. These proteomic profiles identified functional differences between breast cancer subtypes, related to energy metabolism, cell growth, mRNA translation and cell-cell communication. Furthermore, we derived a 19-protein predictive signature, which discriminates between the breast cancer subtypes, through Support Vector Machine (SVM)-based classification and feature selection. The deep proteome profiles also revealed novel features of breast cancer subtypes, which may be the basis for future development of subtype specific therapeutics.
2017-03-29 | MSV000080757 | MassIVE
Project description:Deep proteomic evaluation of primary and cell line motoneuron disease models delineates major differences in neuronal characteristics
2022-01-14 | E-PROT-12 | ExpressionAtlas